Business Wire

CSG and Cellusys Drive New Era of Innovation in Roaming

Share

Mobile operators face growing challenges in managing complex roaming agreements, settlements and network quality, impacting their customer experience and business growth. Today,CSG® (NASDAQ: CSGS) announced a new partnership with Cellusys, the industry leader in roaming steering, fraud and security and analytics solutions for mobile operators, that will address these pain points and boost innovation in the global roaming landscape.

“In any rapidly evolving industry, businesses need best-of-breed solutions that can promote their growth to stay ahead of the curve,” said Finn Kornbo, Executive Product Director, Digital Wholesale, CSG. “That's why we're partnering with Cellusys to combine our expertise and make it easy for mobile operators to optimize their roaming workflows, improve customer satisfaction and capitalize on emerging technologies like 5G and IoT.”

This partnership leverages the strengths of both CSG and Cellusys to deliver a unified solution portfolio that streamlines the roaming process, enhances customer experiences and unlocks new revenue streams. With real-time visibility of all roaming conditions and activity, mobile operators are empowered to turn subscriber insights into effortless customer experiences, without compromising roaming revenues. Key features of the CSG and Cellusys solution include:

  • Intelligent Roaming Steering: Data-driven network selection to optimize cost, quality and subscriber satisfaction, ensuring the best possible experience.
  • Proactive Testing: Active network quality monitoring that identifies and resolves issues before they impact subscribers, guaranteeing seamless connectivity.
  • Smart Settlement: Streamlined automated reconciliation to gain flexibility and control over roaming products and agreements while reducing costs and reliance on data clearing houses.
  • Comprehensive Analytics: In-depth reports and dashboards that provide actionable insights, so operators can make informed decisions and optimize their roaming strategies.

“Our partnership with CSG is a game-changer for the industry and reflects our commitment to innovation and our dedication to helping mobile operators succeed in a complex and competitive landscape,” said Brendan Cleary, CEO, Cellusys. “By integrating Cellusys’ award-winning roaming management systems with CSG’s roaming testing and settlement leadership, we offer operators a best-of-breed, one-stop solution that addresses every aspect of the roaming process moving into the 5G era.”

Get the facts on CSG’s roaming testing capabilities and learn why Kaleido Intelligence and Rocco named Cellusys the #1 roaming steering vendor.

About CSG

CSG empowers companies to build unforgettable experiences, making it easier for people and businesses to connect with, use and pay for the services they value most. Our customer experience, billing and payments solutions help companies of any size make money and make a difference. With our SaaS solutions, company leaders can take control of their future and tap into guidance along the way from our fiercely committed and forward-thinking CSGers around the world.

Want to be future-ready and a change-maker like the global brands that trust CSG? Visit csgi.com to learn more.

About Cellusys

Founded in 2005 and serving over one billion subscribers, Cellusys is an industry leader in fraud and security and roaming management systems for mobile operators. The company offers a wide range of products and services designed to give mobile operators visibility and control of their voice, signalling, data and messaging traffic. Cellusys has won numerous innovation awards and is ranked as a Tier-1 vendor offering solutions for fraud and security, roaming and analytics.

For more information, please visit cellusys.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240916147580/en/

Contacts

CSG
Kristine Østergaard
Public Relations
+44 (0)79 2047 7204
kristine.ostergaard@csgi.com

John Rea
Investor Relations
+1 (210) 687-4409
john.rea@csgi.com

Cellusys
Eva Zloch
Public Relations
+34644493439
eva@cellusys.com

(c) 2024 Business Wire, Inc., All rights reserved.

Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Vertex Announces US FDA Approval of ALYFTREK ™ , a Once-Daily Next-in-Class CFTR Modulator for the Treatment of Cystic Fibrosis20.12.2024 21:46:00 CET | Press Release

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that the U.S. Food and Drug Administration (FDA) has approved ALYFTREK (vanzacaftor/tezacaftor/deutivacaftor), a once-daily next-in-class triple combination cystic fibrosis transmembrane conductance regulator (CFTR) modulator for the treatment of cystic fibrosis (CF) in people 6 years and older who have at least one F508del mutation or another mutation in the CFTR gene that is responsive to ALYFTREK. See below for Important Safety Information, including a Boxed Warning. “ALYFTREK is our fifth CFTR modulator to secure FDA approval and represents another significant milestone in our journey to serially innovate and to improve the lives of people living with cystic fibrosis,” said Reshma Kewalramani, M.D., Chief Executive Officer and President of Vertex. “Our north star for more than 20 years has been to address the underlying cause of cystic fibrosis, treat more people with this disease, and bring more people to normal le

Vertex Announces U.S. FDA Approval for TRIKAFTA (elexacaftor/tezacaftor/ivacaftor and ivacaftor) to Include Additional Non- F508del TRIKAFTA-Responsive Variants20.12.2024 21:35:00 CET | Press Release

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the U.S. Food and Drug Administration (FDA) has approved the expanded use of TRIKAFTA® (elexacaftor/tezacaftor/ivacaftor and ivacaftor) for the treatment of people with cystic fibrosis (CF) ages 2 and older who have at least one F508del mutation in the cystic fibrosis transmembrane conductance regulator (CFTR) gene or a mutation that is responsive to TRIKAFTA based on clinical and/or in vitro data. In addition, safety information on liver injury and liver failure has been updated from warnings and precautions to a boxed warning. With this approval, 94 additional non-F508delCFTR mutations have been added to the TRIKAFTA label, and approximately 300 additional people with CF in the U.S. are now eligible for a medicine to treat the underlying cause of their disease for the first time. “Since its first approval in 2019, TRIKAFTA has had a transformative impact on tens of thousands of people living with cystic fibrosis,” sai

HSBC Continental Europe Enters Into a Memorandum of Understanding Regarding Potential Sale of HSBC Assurances Vie (France) to Matmut Société d’Assurance Mutuelle20.12.2024 20:32:00 CET | Press Release

Regulatory News: HSBC Continental Europe has signed a Memorandum of Understanding (‘MOU‘) regarding the potential sale of its French life insurance business, HSBC Assurances Vie (France), to Matmut Société d’Assurance Mutuelle (‘Matmut’) (the “Potential Transaction”). HSBC Assurances Vie (France) provides a wide range of life insurance solutions and services, with over 20 billion euros of outstanding assets, net income1 of 77 million euros and a Solvency II ratio of 287% in 2023. As part of the Potential Transaction, HSBC Continental Europe and Matmut would enter into a long-term arrangement for HSBC Global Asset Management (France) to continue to partner with HSBC Assurances Vie (France). HSBC Assurances Vie (France) will continue its existing distribution arrangements. The Potential Transaction would provide customers and employees of HSBC Insurance Life (France) with the opportunity to join one of the leading French mutual insurance groups, which is in full development, and forms pa

SBC Medical Group Co., Ltd. Sells Two Subsidiaries20.12.2024 13:00:00 CET | Press Release

On December 17, 2024, SBC Medical Group Holdings Incorporated (“SBC Medical”, or the “Company”), announced that its subsidiary, SBC Medical Group Co., Ltd. (hereinafter referred to as "SBCMG"), has decided to sell all shares of its subsidiaries, SBC Kijimadaira Resort Co., Ltd. (hereinafter referred to as "Kijimadaira") and Skynet Academy Co., Ltd. (hereinafter referred to as "SNA"), as outlined below. The decision to sell these subsidiaries was made to concentrate SBCMG's management resources on its core medical services business, in line with its strategy of prioritizing and focusing on key business areas. The subsidiaries being sold operate in the following industries: Kijimadaira: Ski resort operations SNA: Flight training operations The shares will be sold to a company wholly owned by Yoshiyuki Aikawa, the CEO of the Company. Since this transaction constitutes a related party transaction, it was deliberated and approved by the Company’s Board of Directors and Audit Committee. To e

Aarhus University: New Global Study Sheds Light on the Learning Crisis: Three Years After COVID-1920.12.2024 13:00:00 CET | Press Release

TIMSS 2023 has revealed an alarming global learning crisis exacerbated by the COVID-19 pandemic. Compared to the long term trend in progress in mathematics and science achievement has not only stalled but reversed when taking school closures into account, with the most vulnerable students facing the steepest losses. Key Findings Global Achievement Decline: A 0.11 standard deviation drop in student performance reflects the pandemic's lasting impact. Disproportionate Impact: Low performers, girls, and language minorities faced losses up to twice the average (0.22 standard deviations), deepening existing inequities. Regional Variations: Countries with prolonged school closures and limited remote learning resources experienced the steepest declines. Why This Matters School closures disrupted the education of over one billion children worldwide, with disadvantaged students suffering the most. “The widening gender gap in STEM fields is particularly troubling,” said Christian Kjeldsen, incomi

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye